Break Wave Lithotripsy for Urolithiasis: Results of the First-in-Human International Multi-Institutional Clinical Trial
Authors:
- Ben H. ChewBCBen H. Chew
- Jonathan D. HarperJHJonathan D. Harper
- Roger L. SurRSRoger L. Sur
- Thomas ChiTCThomas Chi
- Shubha DeSDShubha De
- Anne R. BuckleyABAnne R. Buckley
- Ryan F. PatersonRPRyan F. Paterson
- Victor K. F. WongVWVictor K. F. Wong
- Connor M. ForbesCFConnor M. Forbes
- M. Kennedy HallMHM. Kennedy Hall
- Ross KesslerRKRoss Kessler
- Seth K. BechisSBSeth K. Bechis
Open Access
- 1 October 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (4) , 580-589
Abstract
This study reports on a prospective, multicenter, single-arm, clinical trial utilizing the SonoMotion (San Mateo, California) Break Wave lithotripsy (BWL) device to fragment urinary stones. Patients with a urinary stone underwent a single treatment of 30 minutes and peak negative pressure of 4.5 to 8 MPa. Subjects were contacted and outcomes assessed at 7, 14, and 35 days after treatment, with clinical follow-up and CT imaging 70 ± 14 days postprocedure. The primary objectives were to assess the safety (hematomas, complications, etc) and effectiveness of BWL (any fragmentation, residual fragments ≤4 mm or ≤2 mm, and completely stone-free rate) as assessed via noncontrast CT-kidneys, ureters, and bladder. Forty-four patients with a ureteral (43%) or renal (57%) stone were treated across 5 centers. Stone fragmentation occurred in 88% of cases; 70% had fragments ≤ 4 and 51% ≤ 2 mm, while 49% were completely stone free on CT; no serious adverse events were reported. Eighty-six percent of patients received either no analgesic medication at all (50%) or minor analgesia (36%). After determining optimal therapy settings, 36 patients were treated and the effectiveness improved exhibiting fragmentation in 92% (33/36), residual fragments ≤ 4 mm in 75% and 58% with fragments ≤ 2 mm with 58% completely stone free. Effectiveness was less in subjects with lower pole stones with 81% fragmentation, 71% having fragments ≤ 4 mm, 29% with fragments ≤ 2 mm, and 29% completely stone free; of distal ureteral stone patients, 89% were completely stone free. BWL offered safe and effective noninvasive stone therapy requiring little to no anesthesia and was carried out successfully in nonoperative environments. ClinicalTrials.gov identifier: NCT03811171.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R44DK109779)
- Sonomotion Inc.
This publication has 23 references indexed in Scilit:
- Global Trends in Incidence and Burden of Urolithiasis from 1990 to 2019: An Analysis of Global Burden of Disease Study DataEuropean Urology Open Science, 2022
- Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART IIJournal of Urology, 2016
- Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART IJournal of Urology, 2016
- First in Human Clinical Trial of Ultrasonic Propulsion of Kidney StonesJournal of Urology, 2016
- Fragmentation of Urinary Calculi In Vitro by Burst Wave LithotripsyJournal of Urology, 2015
- A Prospective Randomized Comparison Between Shockwave Lithotripsy and Semirigid Ureteroscopy for Upper Ureteral Stones <2 cm: A Single Center ExperienceJournal of Endourology, 2015
- Risk Factors Survey for Extracorporeal Shockwave Lithotripsy-Induced Renal HematomaJournal of Endourology, 2013
- Quantitative Assessment of Shockwave Lithotripsy Accuracy and the Effect of Respiratory MotionJournal of Endourology, 2012
- Shock Wave Technology and Application: An UpdateEuropean Urology, 2011
- 2007 Guideline for the Management of Ureteral CalculiJournal of Urology, 2007